search
Back to results

ESI With EUS to Differentiate T3 and T4 ESCC (ESI)

Primary Purpose

Esophageal Cancer

Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
Extraesophageal saline injection (ESI)
Sponsored by
Sun Yat-sen University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Esophageal Cancer focused on measuring extraesophageal saline injection (ESI);, esophageal squamous cell carcinoma (ESCC);, esophageal cancer;, endoscopic ultrasonography (EUS)

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

A)Age ranges 18-65 years old, no gander limited;

B)Patients with advanced ESCC (T2-T4) who were confirmed by standard endoscopy and pathologic biopsy;

C)Patients who agree to accept esophagectomy;

D)Patients with normal cardio-pulmonary and blood coagulation function; patients were predicted to be tolerated anesthesia and surgery;

E)Patients who understand the study, are willing to join this study and sign consent inform;

Exclusion Criteria:

  1. Patients with early ESCC of Tis,T1a and T1b stages detected by standard EUS;
  2. Patients cannot tolerate endoscopy and esophagectomy with various reasons;
  3. Patients who have distant metastatic disease or multiple source of malignant tumor;
  4. Patients with blood coagulation disorder;
  5. Patients don't accept endoscopic or surgical resection subsequently;
  6. Patients with poor compliancy.

Sites / Locations

  • Sun Yat-sen University Cancer Center

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Extraesophageal saline injection (ESI)

Arm Description

Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively

Outcomes

Primary Outcome Measures

Number of participants with adverse events
Adverse events included bleeding due to great vessel split, asphyxia, esophageal perforation, acute heart failure or acute mediastinum inflammation during/post ESI.

Secondary Outcome Measures

Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI

Full Information

First Posted
August 20, 2013
Last Updated
August 22, 2013
Sponsor
Sun Yat-sen University
search

1. Study Identification

Unique Protocol Identification Number
NCT01930630
Brief Title
ESI With EUS to Differentiate T3 and T4 ESCC
Acronym
ESI
Official Title
Extraesophageal Saline Injection Combined With EUS to Differentiate Between T3 and T4 Stage Esophageal Squamous Cell Carcinoma - A PhaseⅠTrial
Study Type
Interventional

2. Study Status

Record Verification Date
August 2013
Overall Recruitment Status
Unknown status
Study Start Date
October 2013 (undefined)
Primary Completion Date
September 2014 (Anticipated)
Study Completion Date
October 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Sun Yat-sen University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
By using a novel technique of extraesophageal saline injection (ESI),the esophagus is to be separate from the adjacent organs.The space between esophagus and adjacent organs can be detected by endoscopic ultrasonography enhanced with ESI.Therefore, ESI plus with EUS is to be differentiate between T3 and T4 stage esophageal squamous cell carcinoma (ESCC). The objective of this Phase Ⅰstudy is to confirm the safety and efficacy of ESI.
Detailed Description
Esophageal cancer (EC) is one of the most common malignant tumors in the world, and China has the highest incidence of esophageal squamous cell carcinoma (ESCC).According to the TNM staging system of the Union for International Cancer Control (UICC) (7th Edition, 2012), EC invades the esophageal adventitia at the T3 stage; invades the pleura, pericardium and diaphragm at the T4a stage; and involves adjacent vital organs (mainly the thoracic aorta, aortic arch, trachea, tracheal bifurcation, and spine) at the T4b stage.It is considered that T3- and T4a-stage tumors can be surgically resected, while tumors at the T4b stage are not suitable for surgical resection.Therefore, it is important for physicians and patients to know whether the tumor has metastasized to adjacent organs before considering resection. The preoperative stage is unclear in many cases of progressive disease and the involvement of vital organs is only discovered by exploratory thoracotomy, because of which the resection may need to be terminated prematurely, leading to unnecessary injuries.Therefore, accurate preoperative staging of EC, especially during the later stages, is important for deciding the appropriate therapeutic option and evaluation of the prognosis. The imaging methods used for preoperative staging of EC include endoscopic ultrasonography (EUS). However, EUS has poor accuracy in advanced ESCC, especially in T3 and T4 stage ESCC. Therefore, it is necessary to improve the preoperative accuracy of EUS for advanced EC. Since extraesophageal space contains loose connective tissue and saline can permeate into extraesophageal space and separate esophagus from adjacent organ; furthermore, saline serves as an EUS contrast agent (negative) and is detected by EUS.Therefore, we envisaged that if saline is directly injected into extraesophageal space, the separation between the esophageal adventitia and its adjacent organs (especially the thoracic aorta, arcus aortae, and tracheal bifurcation) can be observed by EUS. In our recent experiment in canine model, guided by EUS,extraesophageal saline injection was successfully conducted and saline separated esophageal adventitia from adjacent organs including thoracic aorta, arcus aortae, trachea and bronchial bifurcation without any complication.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Esophageal Cancer
Keywords
extraesophageal saline injection (ESI);, esophageal squamous cell carcinoma (ESCC);, esophageal cancer;, endoscopic ultrasonography (EUS)

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Extraesophageal saline injection (ESI)
Arm Type
Experimental
Arm Description
Extraesophageal saline injection (ESI) guided by EUS in patients with advanced ESCC preoperatively
Intervention Type
Device
Intervention Name(s)
Extraesophageal saline injection (ESI)
Other Intervention Name(s)
Extraesophageal saline injection;, Mucosal needle;, EUS:Fujinon7000(EG-530UR and EG-530UT)
Intervention Description
The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
Primary Outcome Measure Information:
Title
Number of participants with adverse events
Description
Adverse events included bleeding due to great vessel split, asphyxia, esophageal perforation, acute heart failure or acute mediastinum inflammation during/post ESI.
Time Frame
10 days
Secondary Outcome Measure Information:
Title
Efficacy of extraesophageal saline separating esophagus from adjacent organs detected by EUS or computerized tomography (CT) just after ESI
Time Frame
30 minutes

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: A)Age ranges 18-65 years old, no gander limited; B)Patients with advanced ESCC (T2-T4) who were confirmed by standard endoscopy and pathologic biopsy; C)Patients who agree to accept esophagectomy; D)Patients with normal cardio-pulmonary and blood coagulation function; patients were predicted to be tolerated anesthesia and surgery; E)Patients who understand the study, are willing to join this study and sign consent inform; Exclusion Criteria: Patients with early ESCC of Tis,T1a and T1b stages detected by standard EUS; Patients cannot tolerate endoscopy and esophagectomy with various reasons; Patients who have distant metastatic disease or multiple source of malignant tumor; Patients with blood coagulation disorder; Patients don't accept endoscopic or surgical resection subsequently; Patients with poor compliancy.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jian-jun Li, MD & PhD
Phone
+862087343381
Email
lijj@sysucc.org.cn
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jian-jun Li, MD & PhD
Organizational Affiliation
Sun Yat-sen University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Sun Yat-sen University Cancer Center
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510060
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xin-xi Zhou, MD
Phone
+862087343135
Email
zhouxx@sysucc.org.cn
First Name & Middle Initial & Last Name & Degree
Jian-jun Li, MD & PhD

12. IPD Sharing Statement

Learn more about this trial

ESI With EUS to Differentiate T3 and T4 ESCC

We'll reach out to this number within 24 hrs